Treating Hypercalcemia in Patients with Cancer
Hypercalcemia is one of the most common laboratory abnormalities in patients with cancer, and oncologists should know how to identify and treat it.
Hypercalcemia is one of the most common laboratory abnormalities in patients with cancer, and oncologists should know how to identify and treat it.
Patients with brain cancer are at increased risk of deep vein thrombosis and consequently pulmonary embolism.
Surveillance for cardiotoxicity must be a part of treating patients with monoclonal antibodies.
Underlying malignancy is a potential cause of nonbacterial thrombotic endocarditis, understanding symptoms and treatment options is important.
Fever is a common symptom for patients with cancer who have neutropenia and it is often difficult to determine if they are in infectious in etiology.
Oncology clinicians must balance the cost, benefit, and risk when comparing inpatient versus outpatient care for patients.
Despite promising results, iniparib was found to be ineffective as first-line therapy for patients with metastatic triple-negative breast cancer.
Rolapitant in combination with granisetron and dexamethasone is effective in preventing chemotherapy-induced nausea and vomiting.
New regimen resulted in significantly less chemotherapy-induced nausea and vomiting in multiple myeloma patients.
Patients with NF-1 are up to 4 times more likely to get both benign and malignant neoplasms, in the muscles, skin, and gastrointestinal tract.